AAVogen is a preclinical-stage biotech company that develops gene therapeutics for muscle wasting disease. The management team is well established with field-specific expertise and the science advisory board is internationally recognized. IND-enabling studies with proprietary technology are ongoing while CMC, regulatory and clinical plans have been completed.